Datapoint: FDA Approves Generic Restasis

The FDA on Feb. 2 approved Vitaris’ generic form of AbbVie’s Restasis to treat patients with keratoconjunctivitis sicca, also known as dry eye. Restasis is a top seller for AbbVie, generating $1.2 billion in sales in 2021. This is the drug’s first generic competitor. For the treatment of dry eye, Restasis holds covered or better status for 95% of all insured lives. 44% of covered lives have preferred access to Restasis without utilization management restrictions.

SOURCE: MMIT Analytics, as of 2/7/22

0 Comments
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
May 26

Datapoint: J&J Sees Potential Stelara Rival in Alvotech-Teva Biosimilar

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
May 25

Datapoint: Ohio Counties Offer the Most Medicare Advantage Plans

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
May 24

Datapoint: Dupixent Scores First-in-Class EoE Nod

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today